Background/Aims
Longer exposure to hepatitis C (HCV) or B virus (HBV) and the increased use of hepatitis
treatment might have an impact on liver-related deaths in patients co-infected with
the Human Immunodeficiency Virus (HIV). We describe the proportion of liver-related
deaths among HIV-infected patients in 2005 compared with 2000.
Methods
In a nationwide survey (341 hospital departments involved in HIV management), all
deaths of HIV-infected patients were prospectively reported. Deaths from either cirrhosis,
hepatocellular carcinoma or fulminant hepatitis were defined as liver-related deaths.
Results
Of the 898 deaths reported in 2005, liver-related causes accounted for 15.4%; this
is compared to 13.4% in 2000. Among liver-related deaths, hepatocellular carcinoma
increased from 15% to 25% (p = 0.04). Among hepatocellular carcinoma-related deaths: in 2000, 10% were HCV-infected;
in 2005, 25% were HCV-infected (p = 0.03). Half of the HCV-related deaths had been treated for HCV but 98% remained HCV-RNA
positive at time of death. The proportion of HBV-related deaths remained stable between
2000 and 2005.
Conclusions
Liver-related deaths, mainly liver cancers, have increased in HIV-infected patients
in France despite wide access to HCV treatment. The stability of HBV-related deaths
might be explained by the use of dually active antiretroviral drugs in co-infected
patients.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of HepatologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS.Int J Epidemiol. 2005; 34: 121-130
- Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC joint study group network (MORTAVIC 2003 study).J Viral Hepat. 2007; 14: 183-188
- Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol.J Hepatol. 2005; 42: 799-805
- Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study.Arch Intern Med. 2006; 166: 1632-1641
- Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group.Hepatology. 1999; 30: 1054-1058
- Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection.J Infect Dis. 2001; 183: 1112-1115
- Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.J Acquir Immune Defic Syndr. 2006; 43: 27-34
- Risk factors and causes of death in the Australian HIV observational database.Sex Health. 2006; 3: 103-112
- Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers.AIDS. 2006; 20: 67-71
- Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City.Ann Intern Med. 2006; 145: 397-406
- Steatohepatitis in HIV-infected subjects: pathogenesis, clinical impact and implications in clinical management.Curr HIV Res. 2007; 5: 490-498
- Portal vein thrombosis in a patient with HIV treated with a protease inhibitor-containing regimen.Acta Clin Belg. 2006; 61: 24-29
- Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.JAMA. 2004; 292: 2839-2848
- Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.N Engl J Med. 2004; 351: 451-459
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.AIDS. 2004; 18: F27-F36
- Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.N Engl J Med. 2004; 351: 438-450
- Changes in causes of death among adults infected by the Human Immunodeficiency Virus (HIV) between 2000 and 2005. The “Mortalité 2000 & 2005” surveys (ANRS EN19 and Mortavic).J Acquir Immune Defic Syndr. 2008; 48: 590-598
From the Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA 1993;269:460.
- Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a US-Canadian multicenter study.J Hepatol. 2007; 47: 527-537
- Incidence of and factors associated with hepatocellular carcinoma among hepatitis C virus and human immunodeficiency virus coinfected patients with decompensated cirrhosis.AIDS Res Hum Retroviruses. 2006; 22: 1236-1241
- Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis.Clin Gastroenterol Hepatol. 2006; 4: 1062-1068
- Risk factors for primary hepatocellular carcinoma in black and white Americans in 2000.Clin Gastroenterol Hepatol. 2006; 4: 355-360
- Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy.AIDS Res Hum Retroviruses. 2006; 22: 842-848
- Reversibility of cirrhosis in HIV/HBV coinfection.Antivir Ther. 2007; 12: 279-283
- Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir.Antivir Ther. 2007; 12: 119-122
- Severe liver disease associated with prolonged exposure to antiretroviral drugs.J Acquir Immune Defic Syndr. 2006; 42: 177-182
- Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients.AIDS. 2007; 21: 187-192
- Nodular regenerative hyperplasia: a new serious antiretroviral drugs side effect?.AIDS. 2007; 21: 1498-1499
- Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV.Am J Gastroenterol. 2007; 102: 2536-2540
- Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome.Antivir Ther. 2008; 13: 103-107
- Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States.J Viral Hepat. 2007; 14: 107-115
- Hepatocellular cancer in HIV-infected individuals: tomorrow’s problem?.Expert Rev Anticancer Ther. 2006; 6: 1553-1558
- Regression of liver fibrosis in hepatitis C virus/HIV-co-infected patients after treatment with pegylated interferon plus ribavirin.AIDS. 2006; 20: 2225-2227
- Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial.AIDS Res Hum Retroviruses. 2007; 23: 972-982
Article info
Publication history
Published online: January 05, 2009
Accepted:
November 10,
2008
Received in revised form:
November 1,
2008
Received:
February 14,
2008
Associate Editor: J.M. LlovetFootnotes
☆The authors declare that they do not have anything to disclose regarding funding from industries or conflict of interest with respect to this manuscript. D.S.-C. is supported by the French Agency for Research on AIDS.
Identification
Copyright
© 2009 European Association for the Study of the Liver. Published by Elsevier Inc. All rights reserved.
